Results of a phase II trial of brentuximab vedotin for CD30+ cutaneous T-cell lymphoma and lymphomatoid papulosis

Journal of Clinical Oncology

Volumn 33, Issue 32, 2015, Pages 3759-3765

  Duvic, Madeleine ^a   Tetzlaff, Michael T ^a   Gangar, Pamela ^a   Clos, Audra L ^a   Sui, Dawen ^a   Talpur, Rakhshandra ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRENTUXIMAB VEDOTIN; CD30 ANTIGEN; ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; CAC10-VCMMAE; TUMOR MARKER;

ADULT; AGED; ALOPECIA; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; CUTANEOUS T CELL LYMPHOMA; DEEP VEIN THROMBOSIS; DEHYDRATION; DISEASE SPECIFIC SURVIVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEART INFARCTION; HUMAN; HYPERTRANSAMINASEMIA; INFECTION; LUNG EMBOLISM; LYMPHOMATOID PAPULOSIS; MALE; MYALGIA; MYCOSIS FUNGOIDES; NAUSEA; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; SKIN INFECTION; THORAX PAIN; TREATMENT RESPONSE; UNSTABLE ANGINA PECTORIS; CHEMICALLY INDUCED; CLINICAL TRIAL; DRUG ADMINISTRATION; GENE EXPRESSION REGULATION; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; KAPLAN MEIER METHOD; LYMPHOMA, PRIMARY CUTANEOUS ANAPLASTIC LARGE CELL; LYMPHOMA, T-CELL, CUTANEOUS; MIDDLE AGED; SEZARY SYNDROME; SKIN NEOPLASMS; TREATMENT OUTCOME;

ADULT; AGED; ANTIGENS, CD30; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; DRUG ADMINISTRATION SCHEDULE; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOCONJUGATES; INFUSIONS, INTRAVENOUS; KAPLAN-MEIER ESTIMATE; LYMPHOMA, PRIMARY CUTANEOUS ANAPLASTIC LARGE CELL; LYMPHOMA, T-CELL, CUTANEOUS; LYMPHOMATOID PAPULOSIS; MALE; MIDDLE AGED; NAUSEA; NEUTROPENIA; PERIPHERAL NERVOUS SYSTEM DISEASES; SEZARY SYNDROME; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 84947442955     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.60.3787     Document Type: Article

References (28)

1. Olsen E, Vonderheid E, Pimpinelli N, et al: Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: A proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 110:1713-1722, 2007
2. Josimovic-Alasevic O, Dürkop H, Schwarting R, et al: Ki-1 (CD30) antigen is released by Ki-1-positive tumor cells in vitro and in vivo: I. Partial characterization of soluble Ki-1 antigen and detection of the antigen in cell culture supernatants and in serum by an enzyme-linked immunosorbent assay. Eur J Immunol 19:157-162, 1989
3. Francisco JA, Cerveny CG, Meyer DL, et al: cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 102:1458-1465, 2003
4. Deng C, Pan B, O'Connor OA: Brentuximab vedotin. Clin Cancer Res 19:22-27, 2013
5. Bradley AM, Devine M, DeRemer D: Brentuximab vedotin: An anti-CD30 antibody-drug conjugate. Am J Health Syst Pharm 70:589-597, 2013
6. Duvic M: CD30+ neoplasms of the skin. Curr Hematol Malig Rep 6:245-250, 2011
7. Kadin ME, Carpenter C: Systemic and primary cutaneous anaplastic large cell lymphomas. Semin Hematol 40:244-256, 2003
8. Kempf W, Pfaltz K, Vermeer MH, et al: EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders Lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Blood 118:4024-4035, 2011
9. Talpur R, Jones DM, Alencar AJ, et al: CD25 expression is correlated with histological grade and response to denileukin diftitox in cutaneous T-cell lymphoma. J Invest Dermatol 126:575-583, 2006
10. Kadin ME, Levi E, Kempf W: Progression of lymphomatoid papulosis to systemic lymphoma is associated with escape from growth inhibition by transforming growth factor-beta and CD30 ligand. Ann N Y Acad Sci 941:59-68, 2001
11. Kunishige JH, McDonald H, Alvarez G, et al: Lymphomatoid papulosis and associated lymphomas: A retrospective case series of 84 patients. Clin Exp Dermatol 34:576-581, 2009
12. Horwitz SM, Olsen EA, Duvic M, et al: Review of the treatment of mycosis fungoides and Sézary syndrome: A stage-based approach. J Natl Compr Canc Netw 6:436-442, 2008
13. Talpur R, Singh L, Daulat S, et al: Long term outcomes of 1263 patients with mycosis fungoides and Sézary syndrome from 1982 to 2009. Clin Cancer Res 18:5051-5060, 2012
14. Vidulich KA, Talpur R, Bassett RL, et al: Overall survival in erythrodermic cutaneous T-cell lymphoma: An analysis of prognostic factors in a cohort of patients with erythrodermic cutaneous T-cell lymphoma. Int J Dermatol 48:243-252, 2009
15. Diamandidou E, Colome-Grimmer M, Fayad L, et al: Transformation of mycosis fungoides/Sezary syndrome: Clinical characteristics and prognosis. Blood 92:1150-1159, 1998
16. Arulogun SO, Prince HM, Ng J, et al: Longterm outcomes of patients with advanced-stage cutaneous T-cell lymphoma and large cell transformation. Blood 112:3082-3087, 2008
17. Younes A, Bartlett NL, Leonard JP, et al: Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 363:1812-1821, 2010
18. Fanale MA, Forero-Torres A, Rosenblatt JD, et al: A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies. Clin Cancer Res 18:248-255, 2012
19. de Claro RA, McGinn K, Kwitkowski V, et al: U. S. Food and Drug Administration approval summary: Brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma. Clin Cancer Res 18:5845-5849, 2012
20. Younes A, Gopal AK, Smith SE, et al: Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol 30:2183-2189, 2012
21. Pro B, Advani R, Brice P, et al: Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: Results of a phase II study. J Clin Oncol 30:2190-2196, 2012
22. Duvic M, Reddy SA, Pinter-Brown L, et al: A phase II study of SGN-30 in cutaneous anaplastic large cell lymphoma and related lymphoproliferative disorders. Clin Cancer Res 15:6217-6224, 2009
23. Olsen EA, Whittaker S, Kim YH, et al: Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: A consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. J Clin Oncol 29:2598-2607, 2011
24. Vega F, Luthra R, Medeiros LJ, et al: Clonal heterogeneity in mycosis fungoides and its relationship to clinical course. Blood 100:3369-3373, 2002
25. van Dongen JJ, Langerak AW, Brüggemann M, et al: Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: Report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 17:2257-2317, 2003
26. Forero-Torres A, Leonard JP, Younes A, et al: A phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Br J Haematol 146:171-179, 2009
27. Rangwala S, Duvic M, Zhang C: Trends in the treatment of cutaneous T-cell lymphoma: Critical evaluation and perspectives on vorinostat. Blood Lymphatic Cancer Target Ther 2:17-27, 2012
28. Martin SJ, Duvic M: Treatment of cutaneous lymphoid hyperplasia with the monoclonal anti-CD20 antibody rituximab. Clin Lymphoma Myeloma Leuk 11:286-288, 2011